A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis.


Tuberculosis (TB) is a communicable disease caused by Mycobacterium tuberculosis (Mtb) and is a major cause of morbidity and mortality. Successful treatment requires strict adherence to drug regimens for prolonged periods of time. Long-acting (LA) delivery systems have the potential to improve adherence. Here, we show the development of LA injectable drug formulations of the anti-TB drug rifabutin made of biodegradable polymers and biocompatible solvents that solidifies after subcutaneous injection. Addition of amphiphilic compounds increases drug solubility, allowing to significantly increase formulation drug load. Solidified implants have organized microstructures that change with formulation composition. Higher drug load results in smaller pore size that alters implant erosion and allows sustained drug release. The translational relevance of these observations in BALB/c mice is demonstrated by (1) delivering high plasma drug concentrations for 16 weeks, (2) preventing acquisition of Mtb infection, and (3) clearing acute Mtb infection from the lung and other tissues.





Published Version (Please cite this version)


Publication Info

Kim, Manse, Claire E Johnson, Alan A Schmalstig, Ayano Annis, Sarah E Wessel, Brian Van Horn, Amanda Schauer, Agata A Exner, et al. (2022). A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis. Nature communications, 13(1). p. 4455. 10.1038/s41467-022-32043-3 Retrieved from https://hdl.handle.net/10161/26257.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.



Jason Eric Stout

Professor of Medicine

My research focuses on the epidemiology, natural history, and treatment of tuberculosis and nontuberculous mycobacterial infections. I am also interested in the impact of HIV infection on mycobacterial infection and disease, and in examining health disparities as they relate to infectious diseases, particularly in immigrant populations.

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.